881 – 890 of 1299
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET
(
- Contribution to journal › Article
-
Mark
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
(
- Contribution to journal › Article
-
Mark
Plasma tau in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Reply : Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
(
- Contribution to journal › Letter
-
Mark
Early- versus Late-Onset Alzheimer’s Disease—Differences in Functional Impairment.
2016) 9th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
-
Mark
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia
(
- Contribution to journal › Article
-
Mark
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology
(
- Contribution to journal › Article